Dallas、TXにおける前立腺がんの臨床試験
Dallasとその周辺地域（約30マイル以内）の拠点で、前立腺がんに関する36件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- UT Southwest Simmons Cancer Center, Dallas
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
被験者募集中第3相
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
被験者募集中第2相
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
被験者募集中第2相
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
被験者募集中第3相
- Texas Oncology - DFW ( Site 8001), Dallas
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
被験者募集中第3相
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital, Dallas
- University of Texas Southwestern Simmons Cancer Center - Redbird, Dallas
- 他2件
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
被験者募集中第2/3相
- Texas Oncology, Dallas
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
被験者募集中第3相
- University of Texas Southwestern Medical Center, Dallas
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
被験者募集中第3相
- Parkland Health & Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0039), Dallas
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
被験者募集中第3相
- Urology Clinics of North Texas, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
被験者募集中第1相
- SCRI at Mary Crowley, Dallas
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
被験者募集中第3相
- Urology Clinics Of North Texas, Dallas
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
被験者募集中第2相
- University of Texas Southwestern Medical Center, Dallas
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
被験者募集中第1/2相
- University of Texas Southwestern Medical Center, Dallas
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
被験者募集中第3相
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
被験者募集中第2相
- University of Texas Southwestern Medical Center, Dallas
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
被験者募集中第3相
- Dallas VA Medical Center, Dallas
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
被験者募集中第1相
- Urology Clinics of North Texas, Dallas
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
被験者募集中第2相
- UT Southwestern Medical Center-Dallas, Dallas
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
被験者募集中第3相
- UT Southwestern Medical Center, Dallas
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
被験者募集中第4相
- Univ of Texas Southwest Med Center, Dallas
Outcomes of Focal Ablation for Prostate Cancer
被験者募集中観察研究
- UTSW, Dallas
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
被験者募集中第3相
- UT Southwestern Medical Center, Dallas
Study of AZD0754 in Participants With Metastatic Prostate Cancer
被験者募集中第1/2相
- Research Site, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
被験者募集中第1相
- Urology Clinics of North Texas, Dallas
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
被験者募集中第4相
- UT Southwestern Medical Center, Dallas
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
被験者募集中観察研究
- Ut Southwestern Medical Center, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Dallas
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
被験者募集中第3相
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Customized TULSA-PRO Ablation Registry
被験者募集中観察研究
- University of Texas Southwestern Medical Center, Dallas
他の都市における前立腺がんの試験
- New York City, NY103件の研究
- Houston, TX76件の研究
- Los Angeles, CA61件の研究
- Boston, MA59件の研究
- St. Louis, MO46件の研究
- Chicago, IL45件の研究
- San Francisco, CA45件の研究
- Philadelphia, PA44件の研究
- Baltimore, MD43件の研究
- Nashville, TN42件の研究
- Seattle, WA42件の研究
- Washington, DC38件の研究
Dallasにおける他の研究
- 乳がん55件の研究
- 非小細胞肺癌52件の研究
- 転移性癌42件の研究
- 心不全42件の研究
- がん（全種類）37件の研究
- 大腸癌33件の研究
- 肥満症30件の研究
- 卵巣がん28件の研究
- 膀胱癌27件の研究
- 肺がん27件の研究
- 子宮内膜がん24件の研究
- 心血管疾患23件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。